Data from a phase 2 trial of its brain cancer vaccine should come this year, and that could lead to the initiation of a phase 3 trial. 4Q, 2013 Prophage is Agenus’ cancer vaccine that is based on its heat shock protein technology. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and with Janssen Sciences Ireland UC and includes several candidates in Phase 2 trials, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials. The study started in August 2010. This grant, R21 AI81072 was the one and only grant the NIH ever awarded (by accident) to my laboratory for the purpose of supporting the development of a live-attenuated HSV-2 vaccine. The biotechnology company Agenus recently published results from a Phase 2 clinical study, demonstrating that >90% of patients treated with the company‘s brain cancer vaccine Prophage Series G-200 were alive at six months after surgery and 30% were alive at 12 months.
Its royalties in accordance with my sales assumptions would be $4 million in 2016, $4 million in 2017 and $7 million in 2024. The HSV-2 0ΔNLS vaccine strain contains an in-frame deletion that removes ICP0’s nuclear localization signal (0ΔNLS), and thus prevents ICP0 from serving as a co-activator of viral mRNA synthesis. Cardiologists Dr Ramanan Kumareswaran and Dr Sheldon Singh tried to figure out what they could do to reduce the number of shocks in (their clinic’s) ICD population during the flu season. Currently there are over 20 vaccines that use QS-21 as an adjuvant. GSK scientists, including Dr Slaoui, realised that designing a vaccine for malaria required first helping the immune system to recognise the parasite so it could mount a defence. Such a “therapeutic HSV-2 vaccine” could be used to reduce the frequency and duration of genital herpes outbreaks in those ~40 million people worldwide who suffer from this chronic viral disease.
The herpes virus specifically targets cells with high levels of this protein, the researchers said. The much smaller VP4 protein has a more extended structure, and lies at the interface between the capsid and the RNA genome. Nov 09, 2015 In the past two months, new therapies for the prevention and treatment of Herpes Simplex Virus (HSV-2) have showed some promising results. J Clin Oncol. QS-21 is best known for its ability to stimulate antibody, or humoral, immune response, and has also been shown to activate cellular immunity. Well, you’ve most likely acquired at least one type of HPV in your life; probably a few of them, although for most of us, they’re harmless.
With the Company expecting to submit to the FDA again sometime this year (with the requested data from the last submission), things are starting to look the way they did between the middle of 2014 and the middle of 2015 for this ticker. Maybe as people find a way to move beyond smoking and beat their addiction, the number of patients who suffer from lung cancer will decrease. Gupta received her Bachelor and Medical Degrees from the University of Zambia and completed her post-doctoral medical training at Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, Children’s Hospital of Philadelphia, and the University of Pennsylvania, where she was faculty, and led a fully funded research laboratory examining host immune responses to viral infections, and advisor for pharmaceutical companies on vaccines and antivirals development. The adjuvant system used in the candidate vaccine is AS01 (GlaxoSmithKline Vaccines), a liposome-based adjuvant system containing the immunoenhancers 3-O-desacyl-4′-monophosphoryl lipid A (MPL), and the saponin QS-21 (Quillaja saponaria Molina, fraction 21; Antigenics Inc., a wholly owned subsidiary of Agenus Inc, Lexington, Massachusetts) [8, 9]. Dr. If so I would love to be a test subject (if comes back positive) there is a testing sight near me.
The randomization algorithm used a minimization procedure to account for subjects’ underlying disease. The envelope is derived from patches of altered cellular membranes and contains numerous glycoprotein spikes . Mathematical modeling predicts prolonged duration and increased severity of HSV-2 shedding episodes is strongly associated with a low density of CD8+ T cells within genital skin (18). Although contrarian investing takes patience, discipline and the willingness to go against the herd, I have found it to be one of the more lucrative strategies in my arsenal over time.